ER D538G
|
HER2 Negative Breast Cancer
|
ER D538G
|
HER2 Negative Breast Cancer
|
H3B-6545 Sensitive: C2 – Inclusion Criteria
|
H3B-6545 Sensitive: C2 – Inclusion Criteria
|
ER D538G
|
HER2 Negative Breast Cancer
|
ER D538G
|
HER2 Negative Breast Cancer
|
SAR439859 Sensitive: C3 – Early Trials
|
SAR439859 Sensitive: C3 – Early Trials
|
ER D538G
|
Breast Cancer
|
ER D538G
|
Breast Cancer
|
tamoxifen + fulvestrant Sensitive: C4 – Case Studies
|
tamoxifen + fulvestrant Sensitive: C4 – Case Studies
|
ER D538G
|
Hormone Receptor Positive Breast Cancer
|
ER D538G
|
Hormone Receptor Positive Breast Cancer
|
abemaciclib Sensitive: C4 – Case Studies
|
abemaciclib Sensitive: C4 – Case Studies
|
ER D538G
|
Hormone Receptor Positive Breast Cancer
|
ER D538G
|
Hormone Receptor Positive Breast Cancer
|
palbociclib Resistant: C4 – Case Studies
|
palbociclib Resistant: C4 – Case Studies
|
ER D538G
|
Estrogen Receptor Positive Breast Cancer
|
ER D538G
|
Estrogen Receptor Positive Breast Cancer
|
AZD9833 Sensitive: D – Preclinical
|
AZD9833 Sensitive: D – Preclinical
|
ER D538G
|
Estrogen Receptor Positive Breast Cancer
|
ER D538G
|
Estrogen Receptor Positive Breast Cancer
|
lasofoxifene Sensitive: D – Preclinical
|
lasofoxifene Sensitive: D – Preclinical
|
ER D538G
|
Breast Cancer
|
ER D538G
|
Breast Cancer
|
AZD9496 Sensitive: D – Preclinical
|
AZD9496 Sensitive: D – Preclinical
|